// +author:l abbruzzese +author:abbruzzese 
var _ajax_res = {
  hits: 7,

  first: 0,

  results: [

{userid:"everardo", "articletype":"article","pages":"205-211","author":"Everardo D Saad, James L Abbruzzese","year":"2002","title":"Prognostic stratification in UPC: a role for assessing the value of conventional-dose and high-dose chemotherapy for unknown primary carcinoma.","month":"Feb","journal":"Crit Rev Oncol Hematol","publisher":"","volume":"41","number":"2","note":"","tags":"Adult,Antineoplastic Agents,Clinical Trials as Topic,Female,Humans,Male,Middle Aged,Neoplasms, Unknown Primary,Prognosis","booktitle":"","editor":"","abstract":"High-dose chemotherapy has been advocated by some investigators as a means to circumvent drug resistance, thereby improving treatment results in patients with solid tumors. For patients with unknown primary tumors, this hypothesis has only recently undergone limited testing. Two groups (one from the USA and one from Europe) have published their experience with higher doses of chemotherapy in the treatment of UPC. The results are not superior to those reported by other investigators using more standard doses of chemotherapy. Most importantly, chemotherapy trials for UPC are usually conducted in small populations made up of heterogeneous patient subsets with varying sensitivity to chemotherapy. It seems likely that progress in the management of patients with unknown primary cancers will occur as a result of efforts to improve the understanding of the natural history of this disease coupled with the assessment of novel agents targeted against specific biochemical abnormalities that will be demonstrated to be important in the development and maintenance of these malignancies.","address":"","school":"","issn":"1040-8428","doi":"","isi":"","pubmed":"11856596","key":"Saad2002","howpublished":"","urllink":"","refid":26}
,

{userid:"agostino.steffan", "articletype":"article","pages":"37-43","author":"A Da Ponte, E Bidoli, R Talamini, A Steffan, L Abbruzzese, R Tassan Toffola, L De Marco","year":"2005","title":"Pre-storage leucocyte depletion and transfusion reaction rates in cancer patients.","month":"Feb","journal":"Transfus Med","publisher":"","volume":"15","number":"1","note":"","tags":"Adolescent,Adult,Aged,Blood Preservation,Erythrocyte Transfusion,Female,Humans,Leukocyte Reduction Procedures,Male,Middle Aged,Neoplasms","booktitle":"","editor":"","abstract":"Passenger leucocytes transfused with allogenic blood are responsible for potential adverse effects. The impact of pre-storage leucodepletion (in-line filtration) of all whole blood units on transfusion reaction rate among patients suffering from cancer was retrospectively studied, comparing all reactions following red blood cell (RBC) transfusions during 2 years of pre-storage vs. 2 years of selective (bedside) leucodepletion. During selective leucodepletion, 5165 RBC units - of which 2745 were bedside filtered units- were transfused to 866 patients. Twenty-eight reactions were recorded: 22 (15 in the bedside group) febrile non-haemolytic transfusion reactions (FNHTR) and six allergic reactions (five in the bedside group). The overall percentage of reactions was 0.54 (0.76 for bedside) and 0.42 for FNHTR (0.54 for bedside). During pre-storage leucodepletion, 4116 RBC units were transfused to 841 patients. Eleven reactions were recorded: four FNHTR and seven allergic reactions (urticaria). The percentage of reactions for transfused RBC units was 0.26 (0.09 for FNHTR). Comparison between pre-storage filtration and bedside filtration with regard to FNHTR showed an odds ratio of 2.80 (95% confidence interval = 0.83-14.87) for bedside filtration. The study suggests that, for transfused patients affected by cancer, pre-storage leucodepletion is more effective than selective (bedside) filtration in reducing the incidence of transfusion reactions (FNHTR).","address":"","school":"","issn":"0958-7578","doi":"10.1111\/j.1365-3148.2005.00546.x","isi":"","pubmed":"15713127","key":"DaPonte2005","howpublished":"","urllink":"","refid":5}
,

{userid:"nicola.perrotti", "refid":47,"repocollections":"","attachment":"","_thumb":"","articletype":"article","sectionheading":"","title":"Determination of SGK1 mRNA in non-small cell lung cancer samples underlines high expression in squamous cell carcinomas.\r\n","year":"2012","author":"Abbruzzese C, Mattarocci S, Pizzuti L, Mileo AM, Visca P, Antoniani B, Alessandrini G, Facciolo F,\r\nAmato R, D'Antona L, Rinaldi M, Felsani A, Perrotti N, Paggi MG. \r\n","journal":"JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH","volume":"12","number":"","pages":"","month":"","doi":"","pubmed":"","pdflink":"","urllink":"","abstract":"","note":"","tags":""}
,

{userid:"everardo", "articletype":"article","pages":"307-313","author":"Paulo M Hoff, Everardo D Saad, Richard Pazdur, Robert Wolff, Yvonne Lassere, Karla R Bogaard, James L Abbruzzese","year":"2004","title":"Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer.","month":"Aug","journal":"Invest New Drugs","publisher":"","volume":"22","number":"3","note":"","tags":"Adult,Aged,Antineoplastic Combined Chemotherapy Protocols,Camptothecin,Cohort Studies,Colorectal Neoplasms,Dose-Response Relationship, Drug,Drug Administration Schedule,Female,Humans,Male,Maximum Tolerated Dose,Middle Aged,Neoplasm Metastasis,Neutropenia,Organoplatinum Compounds,Treatment Outcome","booktitle":"","editor":"","abstract":"Both irinotecan and oxaliplatin are active agents in the treatment of patients with metastatic colorectal cancer (MCC). There is a strong preclinical rationale for combining these two agents. We sought to determine the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) of combined irinotecan and oxaliplatin given every three weeks.","address":"","school":"","issn":"0167-6997","doi":"10.1023\/B:DRUG.0000026257.31142.41","isi":"","pubmed":"15122078","key":"Hoff2004","howpublished":"","urllink":"","refid":19}
,

{userid:"everardo", "articletype":"article","pages":"451-453","author":"Everardo D Saad, Eric H Kraut, Paulo M Hoff, Dennis F Moore, Donnah Jones, Richard Pazdur, James L Abbruzzese","year":"2002","title":"Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer.","month":"Oct","journal":"Am J Clin Oncol","publisher":"","volume":"25","number":"5","note":"","tags":"Aged,Antineoplastic Agents,Colorectal Neoplasms,Depsipeptides,Drug Administration Schedule,Female,Humans,Male,Middle Aged,Oligopeptides","booktitle":"","editor":"","abstract":"Dolastatin-10 is a potent inhibitor of microtubule assembly derived from the sea hare, which displayed significant antitumor activity in preclinical models. We conducted a phase II study of dolastatin-10 in patients with advanced colorectal cancer and no prior chemotherapy for metastatic disease. Fourteen patients received doses ranging from 300 microg\/m(2) to 450 microg\/m(2) as an intravenous push every 21 days. There were no major objective responses. Toxicity was mainly hematologic, with grade III or IV granulocytopenia occurring in 9 of 42 treatment courses. Other toxic effects were generally mild. Dolastatin-10 lacks clinically significant activity in advanced colorectal cancer when used in this dose and schedule.","address":"","school":"","issn":"0277-3732","doi":"","isi":"","pubmed":"12393982","key":"Saad2002","howpublished":"","urllink":"","refid":25}
,

{userid:"jacki.huckins", "articletype":"article","pages":"4531-4540","author":"Motofumi Tanaka, Ping Chang, Yanan Li, Donghui Li, Michael Overman, Dipen M Maru, Salil Sethi, Jonathan Phillips, Gail L Bland, James L Abbruzzese, Cathy Eng","year":"2011","title":"Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer.","month":"Jul","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","publisher":"","volume":"17","number":"13","note":"","tags":"Adaptor Proteins, Signal Transducing,Adult,Aged,Aged, 80 and over,Cell Cycle Proteins,Colonic Neoplasms,DNA Methylation,Female,Humans,Male,Middle Aged,Neoplasm Proteins,Neoplasm Staging,Nuclear Proteins,Promoter Regions, Genetic,Recurrence,Retrospective Studies,Survival Analysis","booktitle":"","editor":"","abstract":"This study was designed to determine whether DNA methylation biomarkers are associated with recurrence and survival in colon cancer patients.","address":"","school":"","issn":"1078-0432","doi":"10.1158\/1078-0432.CCR-10-0763","isi":"","pubmed":"21551253","key":"Tanaka2011","howpublished":"","urllink":"","refid":1583}
,

{userid:"everardo", "articletype":"article","pages":"3529-3534","author":"P M Hoff, N Janjan, E D Saad, J Skibber, C Crane, Y Lassere, K R Cleary, S Benner, J Randolph, J L Abbruzzese, R Pazdur","year":"2000","title":"Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer.","month":"Oct","journal":"J Clin Oncol","publisher":"","volume":"18","number":"20","note":"","tags":"Administration, Oral,Adult,Aged,Antineoplastic Combined Chemotherapy Protocols,Combined Modality Therapy,Drug Administration Schedule,Female,Humans,Leucovorin,Male,Middle Aged,Postoperative Care,Preoperative Care,Rectal Neoplasms,Surgical Procedures, Operative,Tegafur,Uracil","booktitle":"","editor":"","abstract":"Preoperative combined-modality therapy for rectal cancer may allow for sphincter preservation, while decreasing recurrence rates and improving the overall prognosis. Oral chemotherapy with uracil and tegafur (UFT) plus leucovorin (LV) may reduce costs and complications associated with protracted infusions of fluorouracil. Our goal was to evaluate the safety of UFT plus LV combined with preoperative radiation and determine the maximum-tolerated dose (MTD) and dose-limiting toxicity (DLT) of UFT plus LV in this setting.","address":"","school":"","issn":"0732-183X","doi":"","isi":"","pubmed":"11032595","key":"Hoff2000","howpublished":"","urllink":"","refid":32}
  ]
}

;
ajaxResultsLoaded(_ajax_res);